Adaptive blinded sample size adjustment for comparing two normal means-a mostly Bayesian approach

Pharmaceutical Statistics

Volumn 11, Issue 3, 2012, Pages 230-240

  Hartley, Andrew M ^a  

^a Pharmaceutical Product Development   (United States)

Author keywords

adaptive designs; Bayesian analysis; clinical trials; sample size; sample size re estimation

Indexed keywords

ARTICLE; BAYES THEOREM; BLINDED SAMPLE SIZE REDETERMINATION; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; ERROR; INFORMATION PROCESSING; KNOWLEDGE BASE; MATHEMATICAL MODEL; OBSERVER BIAS; POWER ANALYSIS; PREDICTIVE VALUE; PROBABILITY; SAMPLE SIZE; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; VARIANCE; HUMAN; PROCEDURES; SINGLE BLIND PROCEDURE; STATISTICAL MODEL;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, STATISTICAL; SAMPLE SIZE; SINGLE-BLIND METHOD;

EID: 84861098716     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.538     Document Type: Article

References (33)

1. Chuang-Stein C, Anderson K, Gallo P, Collins S,. Sample size reestimation: a review and recommendations. Drug Information Journal 2006; 40: 475-84. (Pubitemid 44721125)
2. European Medicines Agency. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design, 2007. Document Reference CHMP/EWP/2459/02.
3. US Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. Draft Guidance, 2010.
4. Spiegelhalter DJ, Abrams KR, Myles JP,. Bayesian approaches to clinical trials and health-care evaluation. Wiley: New York, 2004.
5. Clarke B, Yuan A,. Closed form expressions for Bayesian sample size. Annals of Statistics 2006; 34 (3): 1293-1330. (Pubitemid 44231164)
6. Adcock CJ,. A Bayesian approach to calculating sample sizes. Journal of the Royal Statistical Society 1988; 37 (4/5): 433-9.
7. Joseph L, Wolfson DB, du Berger R,. Sample size calculations for binomial proportions via highest posterior density intervals. The Statistician 1995; 44: 143-54.
8. Zou KH, Normand SL,. On determination of sample size in hierarchical binomial models. Statistics in Medicine 2001; 20: 2163-82. (Pubitemid 32684636)
9. Pezeshk H,. How many subjects? - a Bayesian approach to the design of a clinical trial. Iranian International Journal of Science 2002; 3 (1): 127-33.
10. Joseph L, du Berger R, Bélisle P,. Bayesian and mixed bayesian likelihood criteria for sample size determination. Statistics in Medicine 1997; 16: 769-781. (Pubitemid 27165682)
11. Joseph L, Wolfson D,. Interval-based versus decision theoretic criteria for the choice of sample size. The Statistician 1997; 46 (2): 145-9. (Pubitemid 127459034)
12. Gelfand AE, Wang F,. A simulation-based approach to Bayesian sample size determination for performance under a given model and for separating models. Statistical Science 2002; 17 (2): 193-208.
13. de Santis F,. Sample size determination for robust Bayesian analysis. Journal of the American Statistical Association 2006; 101 (473): 278-291. DOI: 10.1198/016214505000000510. (Pubitemid 43500042)
14. Brutti P, de Santis F, Gubbiotti S,. Robust Bayesian sample size determination in clinical trials. Statistics in Medicine 2008; 27 (13): 2290-2306. DOI: 10.1002/sim.3175. (Pubitemid 351802895)
15. M'Lan E, Joseph L, Wolfson D,. Bayesian sample size determination for case-control studies. Journal of the American Statistical Association 2006; 101 (474): 760-72. (Pubitemid 43972314)
16. Wang J, Stamey J,. A Bayesian algorithm for sample size determination for equivalence and non-inferiority test. Journal of Applied Statistics 2010; 37 (10): 1749-59.
17. Wang MD,. Sample size reestimation by Bayesian prediction. Biometrical Journal 2007; 49: 365-77. DOI: 10.1002/bimj.200310273.
18. Gaydos B, Anderson KM, Berry D, Burnham N, Chuang-Stein C, Dudinak J, Fardipour P, Gallo P, Givens S, Lewis R, Maca J, Pinheiro J, Pritchett Y, Krams M,. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Information Journal 2009; 43: 539-56.
19. Gould AL, Shih WJ,. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Communications in Statistics-Theory and Methods 1992; 21 (10): 2833-53.
20. Bristol DR, Shurzinske L,. Blinded sample size adjustment. Drug Information Journal 2001; 35: 1123-30. (Pubitemid 34563406)
21. Kieser M, Friede T,. Simple procedures for blinded sample size adjustment that do not affect the type I error rate. Statistics in Medicine 2003; 22: 3571-81. DOI: 10.1002/sim.1585. (Pubitemid 37483535)
22. Friede T, Kieser M,. On the inappropriateness of an EM algorithm based procedure for blinded sample size reestimation. Statistics in Medicine 2002; 21: 165-76. DOI: 10.1002/sim.977. (Pubitemid 34048685)
23. Schmidli H, Bretz F, Racine-Poon A,. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint. Statistics in Medicine 2007; 26 (27): 4925-38. DOI: 10.1002/sim.2957. (Pubitemid 350064914)
24. Uebersax JS,. Bayesian unconditional power analysis, 2007. Available at (accessed 16 August 2011).
25. Searle SR,. Linear models. Wiley: New York, 1971.
26. Box GEP, Tiao GC,. Bayesian inference in statistical analysis. Addison-Wesley: Reading New York, 1973.
27. Berger JO,. Statistical decision theory and bayesian analysis. Springer: New York, 1985.
28. Cheng Y, Su F, Berry DA,. Choosing sample size for a clinical trial using decision analysis. Biometrika 2003; 90 (4): 923-36. (Pubitemid 39047129)
29. Patel NR, Ankolekar S,. A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs. Statistics in Medicine 2007; 26: 4976-88. DOI: 10.1002/sim.2955. (Pubitemid 350064917)
30. Stallard N, Whitehead J, Cleall S,. Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics 2005; 4: 119-28. DOI: 10.1002/pst.164. (Pubitemid 40895567)
31. Halpern SD, Karlawish JH, Berlin JA,. The continuing unethical conduct of underpowered clinical trials. JAMA Jul 17, 2002; 288 (3): 358-62. (Pubitemid 34761615)
32. Cui L, Hung HM, Wang SJ,. Modification of sample size in group sequential trials. Biometrics 1999; 55: 853-7. (Pubitemid 29427088)
33. Hung HM, Cui L, Wang SJ, Lawrence J,. Adaptive statistical inference following sample size modification based on interim review of effect size. American Statistical Association Proceedings of the Joint Statistical Meetings 2002: 1542-1548.